Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

MindRank

Artificial_Intelligence

AI in Healthcare and Digital Health Today—March 2, 2026

This week’s AI in Healthcare and Digital Health update highlights…

by Timos Papagatsias

Artificial_Intelligence

AI in Healthcare and Digital Health Today—January 8, 2026

This roundup covers major developments across artificial intelligence,…

by Timos Papagatsias

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Oncology Video Recap—March 2, 2026
Oncology Today—March 2, 2026
Hematology Today—March 2, 2026
AI in Healthcare and Digital Health Today—March 2, 2026
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”

Tags

AccurKardia ASC47 bemdaneprocel Camoteskimab CD46 ADC CDx CeleCor zalunfiban CGT manufacturing Chronic disease mortality conduction-system pacing cost reduction DIPS Arena EMBER-3 Enzalutamide FDA Digital Health Advisory FG001 Gilead Sciences GLP-1 Receptor Agonists gout flares HOPE-3 IDH1 Jaypirca JUST-AAV knee osteoarthritis live biotherapeutic product Mayo Clinic pediatric asthma AI MET-097i MicroRNAs naxtarubicin OCALIVA PALSONIFY parathyroidectomy PPMS Rinvoq Rituximab Spikevax SRSD107 Stanford Medicine Sutra Medical TG Therapeutics Thyroid Eye Disease Transgene Tyvaso Ver-A-T1D zelasudil

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Oncology Video Recap—March 2, 2026
Oncology Today—March 2, 2026
Hematology Today—March 2, 2026
AI in Healthcare and Digital Health Today—March 2, 2026
Lucid Diligence Brief: Novartis Rhapsido (remibrutinib) goes “beyond CSU”

TAGS

AccurKardia ASC47 bemdaneprocel Camoteskimab CD46 ADC CDx CeleCor zalunfiban CGT manufacturing Chronic disease mortality conduction-system pacing cost reduction DIPS Arena EMBER-3 Enzalutamide FDA Digital Health Advisory FG001 Gilead Sciences GLP-1 Receptor Agonists gout flares HOPE-3 IDH1 Jaypirca JUST-AAV knee osteoarthritis live biotherapeutic product Mayo Clinic pediatric asthma AI MET-097i MicroRNAs naxtarubicin OCALIVA PALSONIFY parathyroidectomy PPMS Rinvoq Rituximab Spikevax SRSD107 Stanford Medicine Sutra Medical TG Therapeutics Thyroid Eye Disease Transgene Tyvaso Ver-A-T1D zelasudil

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy